z-logo
Premium
Myeloablative allogeneic hematopoietic stem cell transplantation in elderly patients
Author(s) -
Ditschkowski M,
Elmaagacli AH,
Trenschel R,
Steckel NK,
Koldehoff M,
Beelen DW
Publication year - 2006
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1111/j.1399-0012.2005.00453.x
Subject(s) - medicine , hematopoietic stem cell transplantation , transplantation , disease , stem cell , stage (stratigraphy) , haematopoiesis , graft versus host disease , hematopoietic cell , surgery , gastroenterology , oncology , paleontology , genetics , biology
  This study aimed to evaluate the outcome following myeloablative allogeneic hematopoietic stem cell transplantation (SCT) among patients older than 50 yr of age. A total of 215 patients with a median age of 57 yr underwent allogeneic hematopoietic SCT for early (41%) or advanced (59%) hematologic malignancies. After a median follow‐up of 36 months a 10‐yr survival estimate of 56 ± 6% could be assessed for patients in early disease stages while patients with advanced diseases showed a significantly decreased survival probability of 31 ± 5% (p < 0.0002). Transplant related mortality (TRM) at day 100 and 365 post‐transplant was 13% and 30% for early but increased to 21% and 49% for advanced disease stages. As major determinants of TRM advanced disease stage (p < 0.0001) and occurrence of grades II–IV graft‐vs.‐host disease (GVHD) (p < 0.0001) were identified. These results show that hematopoietic SCT following myeloablative conditioning is also applicable to elderly patients whereas disease stage and high‐grade GVHD represent the essential prognostic factors for outcome.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here